zetomipzomib
kezar
['lupus', 'zetomipzomib', 'kezar']
yesterday, kezar presented the complete data set from the mission phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class, selective immunoproteasome inhibitor, in #lupusnephritis at the convergence 2022. #acr22 learn more: 
Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease.